SCOTT TREIBER TO HEAD BIOPHARMACEUTICAL DEVELOPMENT FOR THEOREM CLINICAL RESEARCH

(King of Prussia, PA) — Theorem Clinical Research, a leading global contract research organization (CRO) that optimizes trial conduct, has selected Scott P. Treiber, Ph.D., MBA, to spearheadbiopharmaceutical development as executive vice president and general manager. 

"Scott is an extraordinary individual with valuable experience in clinical development, medical affairs, data management and other areas of biopharmaceutical development," said John Potthoff, Theorem president and CEO. "He brings expertise in central nervous system, oncology, cardiology, infectious diseases, respiratory and other prime therapeutic areas. We couldn't have asked for a more perfect fit."

Treiber, an industry veteran with experience at many of the top global CROs, will oversee all aspects of Theorem's biopharmaceutical development, including early phase first-inhuman and proof-of-concept studies and Phase II-IV studies across a wide range of therapeutic areas.

Before joining Theorem, Treiber held executive-level positions within the CRO and pharma industries. Treiber is a founding member of the Clinical Research Exchange and is active in the Chicagoland Chapter of the Association of Clinical Research Professionals. He earned a bachelor's in biology from the University of Iowa, a Ph.D. in biology from the University of California, Santa Cruz, and an MBA from Ellis College at the New York Institute of Technology.

Learn more about Theorem's leadership team and its capabilities at TheoremClinical.com.

Suggested Articles

Data firm Syapse has begun working with the FDA to help bring real-world evidence to bear on the agency’s decisions to approve cancer drugs.

The People-Centered Research Foundation tapped Datavant to de-identify real-world data across its national clinical research network.

Boehringer Ingelheim and MD Anderson Cancer Center have joined forces to create a “virtual” R&D hub so the pair can work on cancer drugs.